Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis

Status Not yet recruiting

Clinical Trial Summary

The goal of this study is to evaluate the efficacy and safety of lenalidomide in the treatment of patients with active cutaneous DM.

Clinical Trial Description

Dermatomyositis (DM) are systemic immune-mediated inflammatory diseases which commonly affected the skin and musculoskeletal system. The cutaneous manifestations of DM are the most important aspect of this disease. Treatment of these cutaneous manifestations is challenging and currently no universally effective drugs exists. Lenalidomide, a second-generation derivative of thalidomide, has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator. Reports on refractory cutaneous manifestations of systemic lupus erythematosus have been mostly performed. The clinical trials of lenalidomide for cutaneous DM are lacking. This is a single-centre, prospective, open-label, single-arm study with Lenalidomide 5mg/day added to the background treatment of GCs and immunosuppressants in DM to evaluate the efficacy and safety of lenalidomide in the treatment of cutaneous DM. ;

Study Design

Related Conditions & MeSH terms

Dermatomyositis

Clinical Trial Details

NCT number	NCT05488327
Study type	Interventional
Source	Jiangxi Provincial People's Hopital
Contact	Lihua Duan, MD
Phone	0791-86895639
Email	lh-duan@163.com
Status	Not yet recruiting
Phase	N/A
Start date	August 1, 2022
Completion date	September 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05833711` - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy	Phase 2
Not yet recruiting	`NCT06284954` - A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis	Phase 2
Completed	`NCT01906372` - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis	Phase 2
Completed	`NCT01813617` - Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis	N/A
Completed	`NCT01165008` - Anakinra in Myositis	Phase 2/Phase 3
Completed	`NCT00004357` - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis	Phase 2
Recruiting	`NCT05832034` - Add-on Intravenous Immunoglobulins in Early Myositis	Phase 2
Recruiting	`NCT05979441` - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy	Phase 3
Not yet recruiting	`NCT05027152` - Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties	N/A
Active, not recruiting	`NCT04723303` - Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)	Early Phase 1
Completed	`NCT03267277` - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis	Phase 2/Phase 3
Recruiting	`NCT05437263` - A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis	Phase 3
Active, not recruiting	`NCT04044690` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)	Phase 3
Recruiting	`NCT05523167` - A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.	Phase 2/Phase 3
Not yet recruiting	`NCT06004817` - Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Recruiting	`NCT03324152` - Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis	N/A
Completed	`NCT02043548` - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	Phase 2
Completed	`NCT03414086` - Predictor of Clinical Response to Acthar in Myositis
Completed	`NCT04628936` - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.	Phase 2
Recruiting	`NCT03293615` - Exercise Capacity of Patients With Dermatomyosis	N/A